Word abonnee en neem Beursduivel Premium

uniQure Terug naar discussie overzicht

AAV5

3 Posts
| Omlaag ↓
  1. Vitavita 2 juli 2017 14:48
    "...and other severe diseases"

    ~ Updated, Long-term Results from the Phase I/II Dose-Escalating Study of AMT-
    060 to be Presented on Monday, July 10, 2017 ~

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 (GLOBE NEWSWIRE)
    -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing
    transformative therapies for patients with severe medical needs, today announced
    that two abstracts have been accepted for presentation at the International
    Society on Thrombosis and Hemostasis (ISTH) Congress held in Berlin, Germany,
    July 8 - 13, 2017.

    "The data to be featured in an oral presentation at ISTH now demonstrate long-
    term safety, efficacy and the potential for broad application of AAV5 in
    hemophilia B," stated Matthew Kapusta, chief executive officer of uniQure. "We
    also look forward to the presentation of clinical data demonstrating successful
    and effective transduction in patients with pre-existing neutralizing antibodies
    to AAV5, further supporting our belief that our AAV5-based gene therapies may
    provide clinical benefits to nearly all patients suffering from hemophilia B and
    other severe diseases
    ."
  2. Vitavita 31 juli 2017 17:45
    @ Prof. Dollar: "Dat Chiesi niet de big pharma is waarmee de wereld wordt veroverd daarin kan ik mij vinden. Aan welke 'potential opportunities' die nota bene gerelateerd zijn aan het programma zouden ze denken?"

    ..deze cliffhanger hebben we ook nog staan...

    "and other severe diseases"

3 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.281
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.044
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.860
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.141
Aedifica 2 828
Aegon 3.257 319.981
AFC Ajax 537 7.010
Affimed NV 2 5.734
ageas 5.843 109.775
Agfa-Gevaert 13 1.853
Ahold 3.536 73.977
Air France - KLM 1.024 34.301
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.681
Alfen 12 15.952
Allfunds Group 3 1.117
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 322
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.755
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.130
AMG 965 125.572
AMS 3 73
Amsterdam Commodities 303 6.512
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 378
Antonov 22.632 153.605
Aperam 91 14.101
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.569
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.079
Aroundtown SA 1 175
Arrowhead Research 5 9.247
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.514
ASML 1.762 76.349
ASR Nederland 18 4.117
ATAI Life Sciences 1 7
Atenor Group 1 322
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.598
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.657

Macro & Bedrijfsagenda

  1. 18 april

    1. NSI Q1-cijfers
    2. Sipef Q1-cijfers
    3. Sligro Q1-cijfers
    4. NL werkloosheid maart
    5. Deliveroo trading update
    6. Easyjet trading update
    7. Econocom Q1-cijfers
    8. PostNL €0,03 ex-dividend
    9. Procter & Gamble Q1-cijfers
    10. VS steunaanvragen - wekelijks
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht